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Background   We previously reported a limb salvage technique by treating tumor-bearing bone 
with liquid nitrogen. We also reported systemic antitumor immunity was enhanced by 
cryotreatment in a murine osteosarcoma (LM8) model. We therefore combined the 
cryotreatment of tumor with dendritic cells to promote tumor-specific immune responses.  
Questions/purposes   We determined whether our technique could enhance systemic immune 
response and inhibit metastatic tumor growth in a murine osteosarcoma model. 
Materials and Methods   To evaluate activation of the immune response, we prepared six 
groups of C3H mice (80 mice total): (1) excision only, (2) dendritic cells without 
reimplantation of the cryotreated primary tumor, (3) reimplantation of the cryotreated primary 
tumor alone, (4) dendritic cells combined with reimplantation of the cryotreated primary 
tumor, (5) dendritic cells exposed to cryotreated tumor lysates without reimplantation of the 
cryotreated primary tumor, and (6) dendritic cells exposed to cryotreated tumor lysates with 
reimplantation of the cryotreated primary tumor.  We then compared and verified the 
activation state of each group's antitumor immunity. 
Results  Mice that received dendritic cells exposed to cryotreated tumor lysates with 
reimplantation of the cryotreated primary tumor group had high serum interferon γ, reduced 
pulmonary metastases, and increased  numbers of CD8(+) T lymphocytes in the metastatic 
areas. 
Conclusions  Combining tumor cryotreatment with dendritic cells enhanced systemic immune 
responses and inhibited metastatic tumor growth.  
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Clinical relevance  We suggest immunotherapy could be developed further to improve the 
treatment of osteosarcoma. 
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The standard treatment of osteosarcoma consists of preoperative chemotherapy, surgical 
tumor excision, and postoperative chemotherapy. Limb-saving surgery is feasible in most 
cases. Advances in osteosarcoma treatment have now achieved a 5-year survival rate of 60% 
to 90% for patients, and limb function after reconstruction continues to improve with time [3, 
16, 30, 46, 47, 49]. 

















reconstruction after osteosarcoma resection. The tumor is resected with an adequate margin, 
and the resected specimen is immersed in liquid nitrogen for 20 minutes to kill all tumor cells. 
After thawing, the specimen is returned to the original place with appropriate internal fixation 
to reconstruct the defect. Compared with heat-treated bones [8, 14], bone genetic proteins and 
native biomechanical structures are preserved after cryotreatment [53]. In one report limb 
function using the  technique of Tsuchiya et al. was rated as excellent in 71.4% of patients, 
and good in 10.7%, as assessed by the functional evaluation system of Enneking [11].  Several 
reports suggest the approach histologically enhanced bone formation when compared 
histologically with pasteurized bone and irradiated bone [43,48].  Another advantage in 
reimplanting cryotreated tumor tissue is its effect on the immune system [50]: tumor tissue 
after cryoablation in situ provokes an immune reaction in patients with breast and prostate 
cancer [6, 8, 39]. Brewer et al. reported metastatic tumors sometimes disappear or shrink after 
in situ cryoablation of the primary tumor with liquid nitrogen [4]. The structure of tumor 
antigens is retained in frozen tumor, and leukocytes probably can recognize these antigens. 
Similar antitumor effects can be expected from our reconstructive procedure of  reimplanting 
tumor-bearing bone after cryotreatment with liquid nitrogen.  
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Nishida et al. observed an inadequate antitumor effect after reimplantation of frozen tumor 
tissue alone [35]. However, the antitumor effect was enhanced by promoting nonspecific 
immune activation by intraperitoneal injection of OK-432, a substance extracted from alpha-












activation of dendritic cells (DCs) that initiate the specific antitumor effect [19]. This type of 
immunotherapy is reportedly effective for breast and prostate cancer [6, 8, 39].  Many groups 
have reported successful immunotherapy for osteosarcoma [5, 15, 18, 20, 22, 24, 25, 33, 34, 
36, 42, 51, 52].  However, the ability to control metastatic lesions and local recurrence does 
not appear to be superior to other adjuvant treatments [2, 7, 13, 23, 29].   
We therefore wondered whether combining cryotreatment and immunotherapy might enhance 
tumor response.  We specifically determined whether: (1) antitumor immunity could be 
enhanced through activation and transfer of DCs combined with reimplantation of the 
cryotreated primary tumor, and (2) metastatic lesions could be prevented owing to the 
involvement of T lymphocytes in a murine osteosarcoma model (LM8). 
Material and Methods 
Using a reported method to induce osteosarcoma [1, 35], we hypodermically implanted 1 x 62 






female C3H mice, 6 to 8 weeks old.  All animals developed tumors.  Two weeks after 
inoculation, we surgically excised the tumors and cryotreated them with liquid nitrogen. We 
established the following six groups (Fig. 1): (1) the tumor was excised with wide margins 14 
days after inoculation (n = 15); (2) the tumor was excised with wide margins 14 days after 
inoculation and bone marrow-derived DCs then were injected  into the subcutaneous 
contralateral subcutaneous gluteal region without reimplantation of the cryotreated primary 69 
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tumor twice a week (n = 15); (3) the tumor was excised with wide margins 14 days after 
inoculation and reimplanted after cryotreatment with liquid nitrogen into the subcutaneous 
contralateral gluteal region to evaluate for local recurrence from frozen tumor tissue (n = 15); 
(4) the tumor was excised 14 days after inoculation and reimplanted after cryotreatment into 
the subcutaneous contralateral gluteal region to evaluate for local recurrence, and DCs then 
were injected twice a week into this secondary site (n = 15); (5) the tumor was excised with 
wide margins 14 days after inoculation and DCs exposed to cryotreated tumor lysates were 
injected twice a week into the subcutaneous contralateral gluteal region without 
reimplantation of the cryotreated primary tumor (n = 15); and (6) the tumor was excised with 
wide margins 14 days after inoculation and reimplanted after the treatment with liquid 
nitrogen into the subcutaneous contralateral gluteal region to evaluate for local recurrence 
(same as Group 3) with the addition of DCs exposed to cryotreated tumor lysates injected 
twice a week (n = 15). We harvested tumor from a mouse another mice, and then the tumor 82 
was treated with liquid nitrogen to create the lysates.  Immunologic effectiveness would not 83 
change even when the transplants were returned to the contralateral flank. We presumed a 84 
85 
86 
systemic immune response would be induced by injecting DCs around the frozen tumor tissue. 
We performed microscopy to determine whether metastasis had occurred in the lungs 2 weeks 
after the tumor inoculation. We confirmed the presence of pulmonary metastases in additional 87 






cells after cryotreatment using liquid nitrogen, in agreement with a previous study [35]. We 
observed no recurrence of the tumor at the primary cite of inoculation after excision. All 
experiments were performed under the guidelines for animal experiments as stipulated by the 
Kanazawa University Graduate School of Medical Science [37]. 
LM8 cells, derived from Dunn osteosarcoma, were provided by the Riken BioResource 
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Center (Saitama, Japan). The cells were maintained in complete medium consisting of RPMI 
1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 μg streptomycin per 
mL, and 100 units penicillin per mL and were cultured at 37° C in 5% CO2. To establish local 
implantation of the tumor and subsequent lung metastasis, the LM8 cells (1 x 106) were 
suspended in 0.2 mL phosphate-buffered saline (PBS) and subcutaneously inoculated into the 
right gluteal region flanks of the mice. All animals had macroscopically and microscopically 
confirmed lung metastases within 
99 









C3H mice were purchased from Sankyo Labo Inc (Toyama, Japan) and housed in a specific 
pathogen-free animal facility in our laboratory. We were not able to accurately determine the 
survival time of each group because the guidelines for animal experiments concerning pain 
required euthanasia in distressed animals. 
Liquid nitrogen (−196° C) was used for cryotreatment. Tumor tissue was collected on gauze 
and soaked in liquid nitrogen for 20 minutes for en bloc tumor tissue freezing. The tumor was 
prethawed at room temperature (20° C) for 15 minutes and then thawed in distilled water (20° 
C) for 15 minutes. The liquid nitrogen-treated tumor tissue was transplanted subcutaneously 








Because the mice were genetically identical, the structure of the major histocompatibility 
complex  (MHC) Class I molecules was such that the T cells would be able to recognize the 
MHC Class I with antigens on the antigen-presenting cells (APCs) [17, 27]. Bone marrow-
derived DCs were generated as described by Lutz and Rössner [28] with minor modifications. 
Briefly, erythrocyte-depleted mouse bone marrow cells obtained from flushed marrow cavities 
(1 x 106 cells/mL) were cultured in complete medium with 20 ng/mL recombinant mouse 
GMCSF (PeproTech EC Ltd, London, UK) in 10-cm tissue culture dishes at 37° C in an 
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atmosphere containing 50 mL CO2 per L. On Days 3 and 6, half of the medium was added to 
the same volume of fresh complete medium and used to replenish the original plates. The 
freeze-thawed tumor lysate was added to the DC cultures on Day 6 at a ratio of five DC 
equivalents to one tumor cell (ie, 5:1) and incubated at 37° C in an atmosphere containing 50 
mL CO2 per L. After 24 hours of incubation, nonadherent cells including DCs were harvested 
by gentle pipetting.  
For fluorescence activated cell sorting (FACS) analysis, DCs were counted with a 
FACSCalibur™ Flow Cytometer (Becton Dickinson, San Jose, CA) and stained with 
fluorochrome-conjugated antibodies (BD Pharmingen, Tokyo, Japan) for the following 
markers: cluster of differentiation (CD)11c, CD80, CD86, I-Ad, and CD40. CD11c was used 
as a marker for all DCs regardless of the degree of maturation, whereas CD80, CD86, I-Ad, 
and CD40 are markers for DCs. Data analysis was performed with CELLQuest™ software 
(Becton Dickinson). The corresponding labeled isotype antibodies served as controls. DCs 
used for vaccination were washed twice, enumerated, and resuspended in PBS at 1 x 106/mL.  
We inoculated LM8 cells (5 x 106) in a mouse to make the tumor lysate. After 4 weeks, we 
resected the tumor mass and soaked the entire tumor in liquid nitrogen to kill the tumor cells. 
We mixed cryonecrotic tissue with DCs at Culture Day 6, after the tumor was defrosted, and 
the homogenate was prepared using PBS. The homogenate was passed through a 0.2-μm filter 
to remove bacteria and tissues and mixed with the DCs for 24 hours.  
After intraperitoneal injection of 5 mL sodium pentobarbital (Somnopentyl®; Kyontsu 
Seiyaku, Tokyo, Japan), mice were euthanized by cervical dislocation and their blood was 
collected. Murine interferon (IFN)-γ and interleukin (IL)-4 release were measured by ELISA 
using Quantikine® (R & D Systems, Minneapolis, MN) according to the manufacturer’s 
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protocol using an Easy Reader EAR340 microtest plate reader (SLT-Labinstruments, Salzburg, 
Austria). 
We measured the area of the pulmonary metastatic lesion on the plane of the maximum cut 142 
dimension from 50 serial histological sections of each lung using ImageJ software (NIH, 143 
Bethesda, MD; http://rsb.info.nih.gov/ij/). All areas were measured manually by drawing lines 
delimiting the edges of the pulmonary metastatic lesion. We compared the mean areas 




















For immunohistochemistry, lung specimens were fixed in 20% formalin and embedded in 
paraffin. For each case, we examined all the blocks of lung tissues of formalin-fixed, paraffin-
embedded tumor tissue. All specimens were decalcified, although we found the 
decalcification step did not influence the immunohistochemistry for any of the stains. Five 
sections for each mouse were cut 4-μm thick. Each section was cut at the maximum diameter. 
CD8(+) T lymphocytes and natural killer (NK) cells in the pulmonary metastatic lesion were 
quantified by measuring the immunohistochemistry-positive cells per unit area in each group. 
Rehydrated tissue sections were incubated with rat monoclonal antibody raised against 
CD8(+) T lymphocytes of mouse origin (Santa Cruz Biotechnology, Santa Cruz, CA) and rat 
monoclonal antibody raised against NK cells of mouse origin (Abcam Plc, Cambridge, UK). 
The two antibodies were diluted 1:50 with PBS. Color reactions were performed at room 
temperature for 15 minutes and coverslips were mounted with glycerol and gelatin. 
We determined differences in serum IFN-γ, serum IL-4, pulmonary metastatic area, and 
number of CD8(+) lymphocytes and NK cells in the metastatic area among the six groups 
using a nonrepeated-measures ANOVA and the Scheffe test. All analyses were conducted with 
SPSS® 11.0 software (SPSS Japan Inc, Tokyo, Japan).   
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We activated antitumor immunity by combining DCs exposed to lysates of cryotreated tumor 
and reimplantation of the cryotreated primary tumor. On Culture Day 7, the ratio of mature 
DCs to immature DCs was increased compared with the ratio at Culture Day 6 (Fig. 2; 
immature DCs, upper left; mature DCs, upper right). Moreover, this increase was more 
apparent in groups incubated with tumor lysate. Serum IFN-γ levels were greater (p < 0.0001) 
in the mice that received DCs combined with reimplantation of the cryotreated primary tumor 
(119.0 ± 7.61 pg/mL) than in the cryotreated primary tumor alone group (37.33 ± 2.58 pg/mL). 
Moreover, the group that received tumor lysate-exposed DCs combined with reimplantation of 
the cryotreated primary tumor (157.33 ± 14 pg/mL) had a greater (p < 0.0001) IFN-γ level 
than the group that received only tumor lysate-exposed DCs without reimplantation of the 
cryotreated primary tumor (120.27 ± 11.29 pg/mL) (Fig. 3). Serum IL-4 was lower (p < 
0.0001) in the mice that received DCs exposed to the lysates of cryotreated tumor and 
reimplantation of the cryotreated primary tumor group (13.33 ± 9.75 pg/mL) than in the 
excision-only group (45.06 ± 5.71 pg/mL) (Fig. 4). 
The enhanced immune response by T lymphocytes reduced metastatic lesions.  Reduction of 
the metastatic area was greater (p < 0.0001) in the group that received DCs without 
reimplantation of the cryotreated primary tumor (15.99 ± 3.93 mm2) than in the excision-only 
group (24.12 ± 3.60 mm2). The reduction of the metastatic area was greater (p < 0.0001) in the 
DCs combined with reimplantation of the cryotreated primary tumor  group (5.39 ± 1.49 
mm2) than in the reimplantation of the cryotreated primary tumor alone group (13.22 ± 2.59 
mm2) (Fig. 5). CD8(+) T lymphocytes gathered in the pulmonary metastatic area in DC-
treated groups, however, NK cells were not recruited to the metastatic area in the DC-treated 
groups compared with the nonDC-treated groups (Fig. 6). The number of CD8(+) T 
 11 
 
AU: Please do not delete query boxes or remove line numbers; ensure you 















lymphocytes per unit area was greater (p < 0.0001) in the DCs combined with reimplantation 
of the cryotreated primary tumor group (8.33 ± 2.57 cells/mm2) than in the reimplantation of 
the cryotreated primary tumor alone group (2.44 ± 0.53 cells/mm2). Mice that received DCs 
exposed to the lysates of cryotreated tumor and reimplantation of the cryotreated primary 
tumor (12.79 ± 2.14 cells/mm2) showed higher (p < 0.0001) levels than the group that 
received DCs exposed to the lysates of cryotreated tumor without reimplantation of the 
cryotreated primary tumor (8.71 ± 2.39 cells/mm2) (Fig. 7). The number of NK cells per unit 
area was greater (p < 0.0001) in the group that received DCs exposed to the lysates of 
cryotreated tumor without reimplantation of the cryotreated primary tumor (3.90 ± 2.17 
cells/mm2) than in the excision-only group (1.20 ± 0.30 cells/mm2) (Fig. 8). The CD8(+)T 
lymphocyte, CD4(+) T lymphocyte, and DC infiltrations in reimplanted tumors was similar to 
that seen with pulmonary metastases (data not shown). 
Discussion  
Various immunotherapies for osteosarcoma have been tried. As standard treatments for 200 
osteosarcoma are ineffectual for many patients, new treatments need to be developed. In the 201 
1970s, immunotherapy for osteosarcoma was reported by Southam et al. [42], Neff and 202 
Enneking [34], and Campbell et al. [5]. In the 1980s, new methods such as the use of 203 
interferons and Bacille de Calmette et Guérin were reported [22, 24, 36]. Another approach 204 
used antiidiotypic antibodies using T cells and liposome encapsulation [18, 51, 52]. Current 205 
methods of immunotherapy for osteosarcoma include peptide therapy or gene transfer therapy 206 
combined with hyperthermia therapy [10, 15, 21, 25, 33].  We asked whether (1) antitumor 207 
immunity could be achieved through activation of DCs combined with reimplantation of the 208 
cryotreated primary tumor and (2) if metastatic lesions would be prevented owing to enhanced 209 
T lymphocytes involvement.   210 
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We acknowledge limitations in this study.  First, we used mice with an identical genetic 
makeup. The structure of the MHC Class I molecules was similar and the T cells could 
recognize the MHC Class I. However, we needed to use DCs from a different (albeit 
genetically identical) mouse to accomplish our adoptive transfer experiments.  We minimized 
the potential for an immune response to nonself antigens by using genetically identical tumor 
tissue and mice.  It would be necessary to use DCs derived from the same individual in 
clinical application, but this could not be achieved in our mouse model. In humans, however, 
monocytes are separated from the patient’s own peripheral blood and DCs can be induced 
from these monocytes.  Second, we could not completely replicate the clinical approach used 
in humans in our mouse model. In clinical cases frozen bone is always returned to the same 
site. However, it was impossible to replicate this in our experimental mouse model in which 
transplanted tumor cells were removed from the tibia and then returned to the same place after 
cryotreatment.  In a preliminary experiment we attempted to do just that and these 20 mice 223 
could not move and died of starvation.   We therefore used the contralateral gluteal region 224 





Antitumor immunity appeared activated through DCs combined with reimplantation of the 
cryotreated primary tumor or by exposing the transferred DC to lysates of cryotreated tumor.  
The use of lymphokine-activated killer (LAK) therapy has been used with other types of 
tumors [26]. However, T lymphocytes, which are the effectors, do not accumulate inside 





DCs is thought to enhance the antitumor effect, but hyperthermia causes proteins to denature, 
and activation of the antitumor effect is often insufficient [37]. Several studies [12, 31, 41] 
report peptide vaccine therapy, but many patients apparently develop immunotolerance [45]. 
Thus, immunotherapy for malignant tumor achieved by these various methods has not been 
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established definitively although investigations continued to try to overcome the major 
hurdles associated with immunotherapy (Table 1). We emphasize the immune response is 
activated by cryotreatment but not by heat-treated tissue. Our method differs from those 
described by others [7, 9, 10,14]. In some regards DCs are believed the principal APCs for 
initiating immune responses in vivo [32]. In comparison with other traditional adjunct 
therapeutic options for cancer, such as radiation therapy and chemotherapy, immunotherapy 
provides a more targeted treatment to the cancer, with potentially fewer detrimental effects on 
noncancerous cells [30, 40].  DCs without sufficient cancer antigens may not have the ability 
to kill tumor cells and present the antigen to T lymphocytes by themselves. Our data suggest 
the antitumor effect in the group that received DCs without reimplantation of cryotreated 
primary tumor was almost the same as that in the reimplantation of cryotreated primary tumor 
alone group. The data further suggest the effects increased only when exposing the DCs to 
tumor lysates in the absence of cryonecrotic primary tumors. However, combining 
reimplantation of cryotreated primary tumor and DCs exposed to cryotreated tumor lysates 
produced synergistic effects. Using reimplantation of cryotreated primary tumor is more 
appropriate for clinical applications. We therefore believe an efficient immune response will 
be activated when DCs recognize tumor antigens appropriately. CD8(+) T cells act as an 
effector by the Th1 route, and this is promoted mainly by IFN-γ and IL-12 [38]. However, IL-
4 [21], IL-6, and IL-10 strengthen humoral immunity. Levels of IFN-γ, IL-2, and IL-12 
generally increase when cell-mediated immunity is activated, and IL-4, IL-6, and IL-10 
increase when humoral immunity is activated. These cytokines act in opposition to maintain 























Our data suggest enhanced T lymphocyte recruitment and function reduces metastatic lesions 257 
258 in a murine osteosarcoma model. Immunoreactivity increased slightly in mice that received 
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DCs exposed to lysates of cryotreated tumor combined with reimplantation of the cryotreated 
primary tumor. NK cells attack the tumor independently of APCs. NK cells attack cells that 
downregulate MHC Class I expression or have a stressed appearance [44]. We observed a 
reduced tumor burden in the groups that received transplanted DCs, which correlated with 
recruitment of CD8 lymphocytes to the tumor site as observed with immunohistochemistry. 
Returning the frozen bone after liquid nitrogen treatment to its original place can be readily 
used in the clinic. After the first cryotreatment, it is possible to perform the treatment again 
using cultured DCs if a patient's tumor cells have been preserved. This approach can therefore 
still be used even after other methods, such as chemotherapy, radiation therapy, or surgery are 
no longer reasonable. Combining DCs pulsed with lysates of cryotreated tumor and 
reimplantation of the cryotreated primary tumor enhanced antitumor effects. We believe the 
approach may be a useful alternative for patients with osteosarcoma when other treatment 
options including chemotherapy, radiotherapy, and surgical treatment have been ineffective.  
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Legends 
Fig. 1 A diagram of the experimental protocol and treatment schedule is shown. Two weeks 
after tumor inoculation, tumors were treated by one of the following methods: (1) excision 
only (n = 15); (2) DCs without reimplantation of the cryotreated primary tumor (n = 15); (3) 
reimplantation of the cryotreated primary tumor (n = 15); (4) DCs pulsed with cryotreated 
tumor lysates and reimplantation of the cryotreated primary tumor (n = 15); (5) DCs pulsed 
with cryotreated tumor lysates without reimplantation of the cryotreated primary tumor (n = 
15); or (6) DCs pulsed with cryotreated tumor  and reimplantation of the cryotreated primary 
tumor (LN) (n = 15). The mice were euthanized and evaluated 6 weeks after tumor 
inoculation.  s.c. = subcutaneous. 
Fig. 2 DC activation status was examined using flow cytometry. DCs at Culture Day 7 (Group 
b) were more mature than DCs at Culture Day 6 (Group a). On Culture Day 7, DC maturity 
was greatest in the groups receiving lysate-primed DCs (Group c) than in those not receiving 
lysate-primed DCs (Group b).  
Fig. 3  A graph of the serum IFN-γ levels in the six treatment groups is shown. The samples 
were collected 28 days after the reimplantation surgery and/or DC adoptive transfer. Mice that 
received DCs exposed to the lysates of cryotreated tumor and reimplantation of the 
cryotreated primary tumor group showed a highest IFN-γ level. Error bars represent SD.  
Fig. 4  A graph of the serum IL-4 in the six treatment groups is shown. Sera were collected 28 
days after the reimplantation surgery and/or DC adoptive transfer. DCs exposed to the lysates 
of cryotreated tumor and reimplantation of the cryotreated primary tumor group showed lower 
level than any other groups. Error bars represent SD.  
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Fig. 5  Reduction of the metastatic area in the six treatment groups is shown. The samples 
were gathered 28 days after the reimplantation surgery and/or DC adoptive transfer. Error bars 
represent SD. 
Fig. 6   
To evaluate CD8(+) T lymphocytes (Figures A, B, C, D, E and F) and NK cells (Figures G, H, 
I, J, K and L) in pulmonary metastasis, immunostaining was performed: (A, G) Group 1, (B, 
H) Group 2, (C, I) Group 3, (D, J) Group 4, (E, K) Group 5, and (F, L) Group 6 A; CD8(+) T 
lymphocytes in Group 1, B; CD8(+) T lymphocytes in Group 2, C; CD8(+) T lymphocytes in 
Group 3, D; CD8(+) T lymphocytes in Group 4, E; CD8(+) T lymphocytes in Group 5, F; 
CD8(+) T lymphocytes in Group 6, G; NK cells in Group 1, H; NK cells in Group 2, I; NK 
cells in Group 3, J; NK cells in Group 4, K; NK cells in Group 5, L; NK cells in Group 6. 
CD8(+) T lymphocytes gathered in group D,E and F. However, they did not gathered in group 
A, B, and C. On the other hand, NK cells were recruited only in group A, B and C.  (Original 
magnification of each figure, x200).    
Fig. 7   The numbers of CD8(+) T lymphocytes per unit area in the six treatment groups are 
shown. The samples were gathered 28 days after the reimplantation surgery and/or DC 
adoptive transfer. DCs exposed to the lysates of cryotreated tumor and reimplantation of the 
cryotreated primary tumor group showed a higher level than any other groups. Error bars 
represent SD.  
Fig. 8  The numbers of NK cells per unit area in the six treatment groups are shown. The 
samples were gathered 28 days after the reimplantation surgery and/or DC adoptive transfer. 
Error bars represent SD. 
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